Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2308
Source ID: NCT00886574
Associated Drug: Cilostazol
Title: Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events
Acronym: CAPPA
Status: UNKNOWN
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: Cilostazol|DRUG: Aspirin
Outcome Measures: Primary: Maximal and mean intima media thickness (IMT) of both common carotid artery of the cilostazol group in comparison with the aspirin group, every 6 months following randomization, for 48 months | Secondary: Events of the ischemic heart disease, every 12 months following randomization, for 48 months|Events of cerebrovascular disease, every 12 months following randomization, for 48 months|Events of peripheral vascular disease, every 12 months following randomization, for 48 months|Events of hemorrhagic vascular complication, every 12 months following randomization, for 48 months
Sponsor/Collaborators: Sponsor: Hanyang University | Collaborators: Ajou University School of Medicine|Kyunghee University Medical Center|Korea University Guro Hospital|Inha University Hospital|Inje University|Hallym University Medical Center
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 400
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION
Start Date: 2009-04
Completion Date: 2014-02
Results First Posted:
Last Update Posted: 2010-06-04
Locations: Inha University Hospital, In Cheon, Korea, Republic of|Hallym University Hospital, Pyungcheon, Korea, Republic of|Hallym University Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Kyung hee University Medical Center, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of
URL: https://clinicaltrials.gov/show/NCT00886574